Haemonetics 3rd Quarter Fiscal Year 2025 Earnings Release Available on Investor Relations Website

06.02.25 12:00 Uhr

Werte in diesem Artikel
Aktien

61,00 EUR 0,00 EUR 0,00%

Financial release accessible online

BOSTON, Feb. 6, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its third quarter fiscal year 2025, which ended December 28, 2024, are available on its Investor Relations website.

The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on February 6, 2025. The conference call and webcast can be accessed with the following information:

In addition, the Company has posted to its Investor Relations website the earnings release that will be referenced on its conference call and webcast, a link to which is available below. 

Direct link to 3Q FY25 Earnings Release: 
https://haemonetics.gcs-web.com/static-files/36134646-a371-4076-87b9-26673f9f10f3

A replay of the conference call and webcast will be available for one year beginning on February 6, 2025, at 11:00 a.m. ET using the conference call webcast link provided in this press release.

ABOUT HAEMONETICS
Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. To learn more about Haemonetics, visit www.haemonetics.com.

Investor Contacts:                                                     


Olga Guyette, Vice President-Investor Relations & Treasury     

David Trenk, Manager-Investor Relations

(781) 356-9763                                                     

(203) 733-4987

olga.guyette@haemonetics.com                           

david.trenk@haemonetics.com  



Media Contact:   


Josh Gitelson, Sr. Director-Global Communications       


(781) 356-9776


josh.gitelson@haemonetics.com 


 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/haemonetics-3rd-quarter-fiscal-year-2025-earnings-release-available-on-investor-relations-website-302368961.html

SOURCE Haemonetics Corporation

Ausgewählte Hebelprodukte auf Haemonetics

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Haemonetics

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Nachrichten zu Haemonetics Corp.

Wer­bung

Analysen zu Haemonetics Corp.

DatumRatingAnalyst
07.08.2019Haemonetics OutperformBarrington Research
08.05.2019Haemonetics OutperformBarrington Research
09.08.2018Haemonetics OutperformBarrington Research
07.02.2018Haemonetics OutperformBarrington Research
08.11.2017Haemonetics OutperformBarrington Research
DatumRatingAnalyst
07.08.2019Haemonetics OutperformBarrington Research
08.05.2019Haemonetics OutperformBarrington Research
09.08.2018Haemonetics OutperformBarrington Research
07.02.2018Haemonetics OutperformBarrington Research
08.11.2017Haemonetics OutperformBarrington Research
DatumRatingAnalyst
07.02.2017Haemonetics Mkt PerformBarrington Research
07.11.2016Haemonetics HoldThe Benchmark Company
11.05.2016Haemonetics HoldThe Benchmark Company
05.11.2015Haemonetics HoldThe Benchmark Company
16.08.2006Update Haemonetics Corp.: HoldStanford Research
DatumRatingAnalyst

Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Haemonetics Corp. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"